Abstract
The utility of platelet autoantibody testing in the management of patients with immune thrombocytopenia (ITP) remains uncertain. Because of low sensitivity reported in prospective studies [1–3], the routine use of platelet autoantibody testing has not been endorsed in recent evidence-based guidelines [4]; however, the ‘ITP syndrome’ [5], which includes primary and secondary forms, is a disorder that may comprise groups of patients with distinct clinical and serological profiles. To better understand the diagnostic, prognostic and pathogenic role of platelet autoantibodies in ITP, further systematic evaluation is required. An efficient way to study platelet autoantibodies in ITP is to incorporate testing into the design of large clinical trials. Multinational proficiency testing has shown that most laboratories can readily identify platelet alloantibodies from coded samples [6]; however, platelet autoantibodies may be more difficult to discern. In addition, large-scale implementation would require standard methods of sample collection, processing and testing. This official report of the Platelet Immunology Scientific Subcommittee of ISTH describes a standardized approach to the implementation of platelet autoantibody testing in ITP clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.